John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments.
The Affects of ENV-101 on IPF
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours